PD-1 Blocker Gets Few, but Durable, Breast Cancer Responses

December 11, 2014 4:56 PM

2 0

SAN ANTONIO -- The anti-PD-1 antibody pembrolizumab (Keytruda) yielded prolonged responses for heavily-pretreated triple-negative breast cancer, albeit few and with some substantial toxicity, an early phase trial showed.

The overall response rate was 18.5% with the immune checkpoint inhibitor in that population, with one of the 27 evaluable patients achieving complete response, Rita Nanda, MD, of the University of Chicago, and colleagues reported here at the San Antonio Breast Cancer Symposium.

Read more

To category page